Web stats for Molecular-cancer - molecular-cancer.com
2.67 Rating by ClearWebStats
molecular-cancer.com is 2 decades 2 years 3 months old. This website has a #1,568,788 rank in global traffic. It has a .com as an domain extension. This website has a Google PageRank of 6 out of 10. This domain is estimated value of $ 480.00 and has a daily earning of $ 2.00. While no active threats were reported recently by users, molecular-cancer.com is SAFE to browse.
Traffic Report of Molecular-cancer
Daily Unique Visitors: | 307 |
Daily Pageviews: | 614 |
Estimated Valuation
Income Per Day: | $ 2.00 |
Estimated Worth: | $ 480.00 |
Search Engine Indexes
Google Indexed Pages: | Not Applicable |
Yahoo Indexed Pages: | Not Applicable |
Bing Indexed Pages: | 41 |
Search Engine Backlinks
Google Backlinks: | Not Applicable |
Bing Backlinks: | 26 |
Alexa BackLinks: | 384 |
Safety Information
Google Safe Browsing: | No Risk Issues |
Siteadvisor Rating: | Not Applicable |
WOT Trustworthiness: | Excellent |
WOT Privacy: | Excellent |
WOT Child Safety: | Excellent |
Website Ranks & Scores
Google Pagerank
PR 6 out of 10
PageSpeed Score
81
Siteadvisor Rating
Not Applicable
Where is molecular-cancer.com server located?
Social Engagement
Facebook Shares: | 8 |
Facebook Likes: | 8 |
Facebook Comments: | 6 |
Twitter Count (Tweets): | Not Applicable |
Linkedin Shares: | Not Applicable |
Delicious Shares: | Not Applicable |
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
H1 Headings: | Not Applicable | H2 Headings: | 4 |
H3 Headings: | 3 | H4 Headings: | 14 |
H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
Total IFRAMEs: | Not Applicable | Total Images: | 20 |
Google Adsense: | Not Applicable | Google Analytics: | UA-9663454-9 |
Websites Hosted on Same IP (i.e. 192.129.25.208)
HTTP Header Analysis
Http-Version: 1.1
Status-Code: 200
Status: 200 OK
Content-Language: en-US
Content-Encoding: gzip
Content-Type: text/html;charset=UTF-8
Cache-Control: max-age=0
Last-Modified: Mon, 02 Jun 2014 15:24:13 GMT
X-UA-Device: classic
Server: BioMed Central Web Server 1.0
Content-Length: 14478
Accept-Ranges: bytes
Date: Mon, 02 Jun 2014 16:10:35 GMT
Connection: keep-alive
X-Cache: HIT
X-Cache-Hits: 12
Status-Code: 200
Status: 200 OK
Content-Language: en-US
Content-Encoding: gzip
Content-Type: text/html;charset=UTF-8
Cache-Control: max-age=0
Last-Modified: Mon, 02 Jun 2014 15:24:13 GMT
X-UA-Device: classic
Server: BioMed Central Web Server 1.0
Content-Length: 14478
Accept-Ranges: bytes
Date: Mon, 02 Jun 2014 16:10:35 GMT
Connection: keep-alive
X-Cache: HIT
X-Cache-Hits: 12
Domain Information for molecular-cancer.com
Domain Nameserver Information
DNS Record Analysis
Host | Type | TTL | Extra |
---|---|---|---|
molecular-cancer.com | A | 1795 |
IP:192.129.25.208 |
molecular-cancer.com | NS | 86400 |
Target:ns12.dnsmadeeasy.com |
molecular-cancer.com | NS | 86400 |
Target:ns13.dnsmadeeasy.com |
molecular-cancer.com | NS | 86400 |
Target:ns10.dnsmadeeasy.com |
molecular-cancer.com | NS | 86400 |
Target:ns15.dnsmadeeasy.com |
molecular-cancer.com | NS | 86400 |
Target:ns11.dnsmadeeasy.com |
molecular-cancer.com | NS | 86400 |
Target:ns14.dnsmadeeasy.com |
molecular-cancer.com | SOA | 86400 |
MNAME:ns10.dnsmadeeasy.com RNAME:dns.dnsmadeeasy.com Serial:2009010142 Refresh:43200 Retry:3600 Expire:1209600 |
molecular-cancer.com | MX | 1800 |
Priority:300 Target:molecular-cancer.com.s200b1.psmtp.com |
molecular-cancer.com | MX | 1800 |
Priority:100 Target:molecular-cancer.com.s200a1.psmtp.com |
molecular-cancer.com | MX | 1800 |
Priority:400 Target:molecular-cancer.com.s200b2.psmtp.com |
molecular-cancer.com | MX | 1800 |
Priority:200 Target:molecular-cancer.com.s200a2.psmtp.com |
Similarly Ranked Websites to Molecular-cancer
Radio Tejano FM | Tu Estacion Incomparable
- radiotejanofm.com
Radio Tejano FM - Transmitiendo en vivo! con la mejor musica. locutoras hermosas y alegres en vivo todos los dias!
Fundraising | Convanto
- convanto.com
Convanto is one of India's leading investment banking firms. It focused on fund raising and consulting early stage start-ups.